Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer
Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study
Venous Thromboembolism
DRUG: Apixaban|DRUG: Dalteparin
Recurrent venous thromboembolism, Primary efficacy outcome: objectively confirmed recurrent VTE occurring during the study period, that means the composite of:

Â· proximal DVT of the lower limbs (symptomatic or unsuspected), DVT of the upper limb (symptomatic), PE (symptomatic or unsuspected), 6 months
Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study